Loading…

Microbial Efficacy Analysis of Potentox, a Fixed Dose Combination of Cefepime Amikacin with Cefepime and Amikacin Alone in a Citrobacter Braaki, Mycobacterium Smegmatis, Acinetobacter Baumanii and Neisseria mucosa

A newly developed extended spectrum fourth generation cephalosporins cefepime, has been shown to have good activity against both gram negative organisms. Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Potentox, a Fixed Dose Combination (FDC)of cefepim...

Full description

Saved in:
Bibliographic Details
Published in:Biomedical & pharmacology journal 2009-06, Vol.2 (1), p.95
Main Authors: Shrivastava, Sanjay Mohan, Shukla, Sanjeev Kumar, Kumar, Shailesh, Chaudhary, Manu
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 1
container_start_page 95
container_title Biomedical & pharmacology journal
container_volume 2
creator Shrivastava, Sanjay Mohan
Shukla, Sanjeev Kumar
Kumar, Shailesh
Chaudhary, Manu
description A newly developed extended spectrum fourth generation cephalosporins cefepime, has been shown to have good activity against both gram negative organisms. Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Potentox, a Fixed Dose Combination (FDC)of cefepime and amikacin has a wider range of susceptibility to any of these drugs individually. The in vitro and in vivo effectiveness of Potentox was studied using a high inoculum of an extended spectrum b-lactamase producing Citrobacter braaki, Mycobacterium smegmatis, Acinetobacter baumanii and Neisseria mucosa strain. This study was aimed at evaluating microbial efficacy of Potentox, a FDC of cefepime and amikacin, in comparison with cefepime and amikacin alone. Efficacy was evaluated on the basis of Minimum Inhibitory Concentration (MIC), Antibiotic Susceptibility Test (AST) analysis in C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa. In case of C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa MIC were found to be in potentox 0.421mg/l, 0.625mg/l, 0.342mg/l and 0.423 mg/l. In cefepime alone the MIC were found to be 1.67mg/l, 0.52mg/l, 0.84mg/l and 2.67 mg/l respectively and in amikacin alone the MIC were found to be 3.34mg/l, 1.67mg/l, 2.67mg/l and 1.0mg/l respectively. Antibiotic susceptibility result are given below. In all organisms under study, potentox was found to have more bacterial inhibiting properties than cefepime and amikacin alone in vitro.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2123635242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2123635242</sourcerecordid><originalsourceid>FETCH-LOGICAL-p98t-24e552d30deabb8fec4a53aef35edef83751f62b2c539fca805fc3af7e8f81da3</originalsourceid><addsrcrecordid>eNpFUNtKw0AQDaJgqf7DgK8NJLvZJH2MsVWhXsC-y2Qzq9Mm2ZrdYPuh_o_xgj7NcK5wjoKJSFQaijSOjoNJNM-SMBWJOA3OndtEUSTiOMvieBJ83LHubcXYwMIY1qgPUHTYHBw7sAYerafO2_0MEJa8pxqurCMobVtxh55t96UqydCOW4Ki5S1q7uCd_es_jF39TxWN7QjGB6FkP5aj9tTDZY-45RncHfQvxEMLTy29tGOPm0Exmsn_yXFosWP-zr4ndm40ILSDtg7PghODjaPz3zsN1svFurwJVw_Xt2WxCnfz3IciIaVELaOasKpyQzpBJZGMVFSTyWWmYpOKSmgl50ZjHimjJZqMcpPHNcppcPETu-vt20DOP2_s0I_ruWcRC5lKNW4uPwH0en3K</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2123635242</pqid></control><display><type>article</type><title>Microbial Efficacy Analysis of Potentox, a Fixed Dose Combination of Cefepime Amikacin with Cefepime and Amikacin Alone in a Citrobacter Braaki, Mycobacterium Smegmatis, Acinetobacter Baumanii and Neisseria mucosa</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Shrivastava, Sanjay Mohan ; Shukla, Sanjeev Kumar ; Kumar, Shailesh ; Chaudhary, Manu</creator><creatorcontrib>Shrivastava, Sanjay Mohan ; Shukla, Sanjeev Kumar ; Kumar, Shailesh ; Chaudhary, Manu</creatorcontrib><description>A newly developed extended spectrum fourth generation cephalosporins cefepime, has been shown to have good activity against both gram negative organisms. Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Potentox, a Fixed Dose Combination (FDC)of cefepime and amikacin has a wider range of susceptibility to any of these drugs individually. The in vitro and in vivo effectiveness of Potentox was studied using a high inoculum of an extended spectrum b-lactamase producing Citrobacter braaki, Mycobacterium smegmatis, Acinetobacter baumanii and Neisseria mucosa strain. This study was aimed at evaluating microbial efficacy of Potentox, a FDC of cefepime and amikacin, in comparison with cefepime and amikacin alone. Efficacy was evaluated on the basis of Minimum Inhibitory Concentration (MIC), Antibiotic Susceptibility Test (AST) analysis in C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa. In case of C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa MIC were found to be in potentox 0.421mg/l, 0.625mg/l, 0.342mg/l and 0.423 mg/l. In cefepime alone the MIC were found to be 1.67mg/l, 0.52mg/l, 0.84mg/l and 2.67 mg/l respectively and in amikacin alone the MIC were found to be 3.34mg/l, 1.67mg/l, 2.67mg/l and 1.0mg/l respectively. Antibiotic susceptibility result are given below. In all organisms under study, potentox was found to have more bacterial inhibiting properties than cefepime and amikacin alone in vitro.</description><identifier>ISSN: 0974-6242</identifier><identifier>EISSN: 2456-2610</identifier><language>eng</language><publisher>Bhopal: Biomedical and Pharmacology Journal</publisher><subject>Acinetobacter ; Amikacin ; Aminoglycoside antibiotics ; Antibiotics ; Antimicrobial agents ; Bacteria ; Bacterial infections ; Cefepime ; Cephalosporins ; Chemotherapy ; Citrobacter ; Infectious diseases ; Inoculum ; Laboratories ; Minimum inhibitory concentration ; Mucosa ; Neisseria ; Nosocomial infections ; Penicillin ; Streptococcus infections ; Studies ; β Lactamase</subject><ispartof>Biomedical &amp; pharmacology journal, 2009-06, Vol.2 (1), p.95</ispartof><rights>2009. This work is licensed under http://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2123635242/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2123635242?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Shrivastava, Sanjay Mohan</creatorcontrib><creatorcontrib>Shukla, Sanjeev Kumar</creatorcontrib><creatorcontrib>Kumar, Shailesh</creatorcontrib><creatorcontrib>Chaudhary, Manu</creatorcontrib><title>Microbial Efficacy Analysis of Potentox, a Fixed Dose Combination of Cefepime Amikacin with Cefepime and Amikacin Alone in a Citrobacter Braaki, Mycobacterium Smegmatis, Acinetobacter Baumanii and Neisseria mucosa</title><title>Biomedical &amp; pharmacology journal</title><description>A newly developed extended spectrum fourth generation cephalosporins cefepime, has been shown to have good activity against both gram negative organisms. Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Potentox, a Fixed Dose Combination (FDC)of cefepime and amikacin has a wider range of susceptibility to any of these drugs individually. The in vitro and in vivo effectiveness of Potentox was studied using a high inoculum of an extended spectrum b-lactamase producing Citrobacter braaki, Mycobacterium smegmatis, Acinetobacter baumanii and Neisseria mucosa strain. This study was aimed at evaluating microbial efficacy of Potentox, a FDC of cefepime and amikacin, in comparison with cefepime and amikacin alone. Efficacy was evaluated on the basis of Minimum Inhibitory Concentration (MIC), Antibiotic Susceptibility Test (AST) analysis in C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa. In case of C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa MIC were found to be in potentox 0.421mg/l, 0.625mg/l, 0.342mg/l and 0.423 mg/l. In cefepime alone the MIC were found to be 1.67mg/l, 0.52mg/l, 0.84mg/l and 2.67 mg/l respectively and in amikacin alone the MIC were found to be 3.34mg/l, 1.67mg/l, 2.67mg/l and 1.0mg/l respectively. Antibiotic susceptibility result are given below. In all organisms under study, potentox was found to have more bacterial inhibiting properties than cefepime and amikacin alone in vitro.</description><subject>Acinetobacter</subject><subject>Amikacin</subject><subject>Aminoglycoside antibiotics</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Cefepime</subject><subject>Cephalosporins</subject><subject>Chemotherapy</subject><subject>Citrobacter</subject><subject>Infectious diseases</subject><subject>Inoculum</subject><subject>Laboratories</subject><subject>Minimum inhibitory concentration</subject><subject>Mucosa</subject><subject>Neisseria</subject><subject>Nosocomial infections</subject><subject>Penicillin</subject><subject>Streptococcus infections</subject><subject>Studies</subject><subject>β Lactamase</subject><issn>0974-6242</issn><issn>2456-2610</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpFUNtKw0AQDaJgqf7DgK8NJLvZJH2MsVWhXsC-y2Qzq9Mm2ZrdYPuh_o_xgj7NcK5wjoKJSFQaijSOjoNJNM-SMBWJOA3OndtEUSTiOMvieBJ83LHubcXYwMIY1qgPUHTYHBw7sAYerafO2_0MEJa8pxqurCMobVtxh55t96UqydCOW4Ki5S1q7uCd_es_jF39TxWN7QjGB6FkP5aj9tTDZY-45RncHfQvxEMLTy29tGOPm0Exmsn_yXFosWP-zr4ndm40ILSDtg7PghODjaPz3zsN1svFurwJVw_Xt2WxCnfz3IciIaVELaOasKpyQzpBJZGMVFSTyWWmYpOKSmgl50ZjHimjJZqMcpPHNcppcPETu-vt20DOP2_s0I_ruWcRC5lKNW4uPwH0en3K</recordid><startdate>200906</startdate><enddate>200906</enddate><creator>Shrivastava, Sanjay Mohan</creator><creator>Shukla, Sanjeev Kumar</creator><creator>Kumar, Shailesh</creator><creator>Chaudhary, Manu</creator><general>Biomedical and Pharmacology Journal</general><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200906</creationdate><title>Microbial Efficacy Analysis of Potentox, a Fixed Dose Combination of Cefepime Amikacin with Cefepime and Amikacin Alone in a Citrobacter Braaki, Mycobacterium Smegmatis, Acinetobacter Baumanii and Neisseria mucosa</title><author>Shrivastava, Sanjay Mohan ; Shukla, Sanjeev Kumar ; Kumar, Shailesh ; Chaudhary, Manu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p98t-24e552d30deabb8fec4a53aef35edef83751f62b2c539fca805fc3af7e8f81da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acinetobacter</topic><topic>Amikacin</topic><topic>Aminoglycoside antibiotics</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Cefepime</topic><topic>Cephalosporins</topic><topic>Chemotherapy</topic><topic>Citrobacter</topic><topic>Infectious diseases</topic><topic>Inoculum</topic><topic>Laboratories</topic><topic>Minimum inhibitory concentration</topic><topic>Mucosa</topic><topic>Neisseria</topic><topic>Nosocomial infections</topic><topic>Penicillin</topic><topic>Streptococcus infections</topic><topic>Studies</topic><topic>β Lactamase</topic><toplevel>online_resources</toplevel><creatorcontrib>Shrivastava, Sanjay Mohan</creatorcontrib><creatorcontrib>Shukla, Sanjeev Kumar</creatorcontrib><creatorcontrib>Kumar, Shailesh</creatorcontrib><creatorcontrib>Chaudhary, Manu</creatorcontrib><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Biomedical &amp; pharmacology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shrivastava, Sanjay Mohan</au><au>Shukla, Sanjeev Kumar</au><au>Kumar, Shailesh</au><au>Chaudhary, Manu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microbial Efficacy Analysis of Potentox, a Fixed Dose Combination of Cefepime Amikacin with Cefepime and Amikacin Alone in a Citrobacter Braaki, Mycobacterium Smegmatis, Acinetobacter Baumanii and Neisseria mucosa</atitle><jtitle>Biomedical &amp; pharmacology journal</jtitle><date>2009-06</date><risdate>2009</risdate><volume>2</volume><issue>1</issue><spage>95</spage><pages>95-</pages><issn>0974-6242</issn><eissn>2456-2610</eissn><abstract>A newly developed extended spectrum fourth generation cephalosporins cefepime, has been shown to have good activity against both gram negative organisms. Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Potentox, a Fixed Dose Combination (FDC)of cefepime and amikacin has a wider range of susceptibility to any of these drugs individually. The in vitro and in vivo effectiveness of Potentox was studied using a high inoculum of an extended spectrum b-lactamase producing Citrobacter braaki, Mycobacterium smegmatis, Acinetobacter baumanii and Neisseria mucosa strain. This study was aimed at evaluating microbial efficacy of Potentox, a FDC of cefepime and amikacin, in comparison with cefepime and amikacin alone. Efficacy was evaluated on the basis of Minimum Inhibitory Concentration (MIC), Antibiotic Susceptibility Test (AST) analysis in C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa. In case of C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa MIC were found to be in potentox 0.421mg/l, 0.625mg/l, 0.342mg/l and 0.423 mg/l. In cefepime alone the MIC were found to be 1.67mg/l, 0.52mg/l, 0.84mg/l and 2.67 mg/l respectively and in amikacin alone the MIC were found to be 3.34mg/l, 1.67mg/l, 2.67mg/l and 1.0mg/l respectively. Antibiotic susceptibility result are given below. In all organisms under study, potentox was found to have more bacterial inhibiting properties than cefepime and amikacin alone in vitro.</abstract><cop>Bhopal</cop><pub>Biomedical and Pharmacology Journal</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0974-6242
ispartof Biomedical & pharmacology journal, 2009-06, Vol.2 (1), p.95
issn 0974-6242
2456-2610
language eng
recordid cdi_proquest_journals_2123635242
source Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Acinetobacter
Amikacin
Aminoglycoside antibiotics
Antibiotics
Antimicrobial agents
Bacteria
Bacterial infections
Cefepime
Cephalosporins
Chemotherapy
Citrobacter
Infectious diseases
Inoculum
Laboratories
Minimum inhibitory concentration
Mucosa
Neisseria
Nosocomial infections
Penicillin
Streptococcus infections
Studies
β Lactamase
title Microbial Efficacy Analysis of Potentox, a Fixed Dose Combination of Cefepime Amikacin with Cefepime and Amikacin Alone in a Citrobacter Braaki, Mycobacterium Smegmatis, Acinetobacter Baumanii and Neisseria mucosa
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A36%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microbial%20Efficacy%20Analysis%20of%20Potentox,%20a%20Fixed%20Dose%20Combination%20of%20Cefepime%20Amikacin%20with%20Cefepime%20and%20Amikacin%20Alone%20in%20a%20Citrobacter%20Braaki,%20Mycobacterium%20Smegmatis,%20Acinetobacter%20Baumanii%20and%20Neisseria%20mucosa&rft.jtitle=Biomedical%20&%20pharmacology%20journal&rft.au=Shrivastava,%20Sanjay%20Mohan&rft.date=2009-06&rft.volume=2&rft.issue=1&rft.spage=95&rft.pages=95-&rft.issn=0974-6242&rft.eissn=2456-2610&rft_id=info:doi/&rft_dat=%3Cproquest%3E2123635242%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p98t-24e552d30deabb8fec4a53aef35edef83751f62b2c539fca805fc3af7e8f81da3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2123635242&rft_id=info:pmid/&rfr_iscdi=true